Linked Life Data

12076840

Source:http://linkedlifedata.com/resource/pubmed/id/12076840

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2002-6-21
pubmed:abstractText
Clobazam (CLB, 1,5-benzodiazepine, 1,5-BZP) has been reported to show unique antiepileptic action profile distinguishing from standard 1,4-BZPs. To further elucidate the action profile of CLB, its effects on the abnormal circling fits (ACFs) and generalized tonic-clonic convulsions (GTCs) in Ihara epileptic rats (IERs), a genetically epileptic mutant, were examined in comparison with conventional antiepileptic drugs (AEDs), a 1,4-BZP, clonazepam (CZP) and a non-BZP, zonisamide (ZNS).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0920-1211
pubmed:author
pubmed:issnType
Print
pubmed:volume
49
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
189-202
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Clobazam shows a different antiepileptic action profile from clonazepam and zonisamide in Ihara epileptic rats.
pubmed:affiliation
Safety Research Laboratories, Department of Safety Pharmacology, Dainippon Pharmaceutical Co., Ltd., 33-94 Enoki-cho, Suita, Osaka, Japan. yoshiki-miura@dainippon-pharm.co.jp
pubmed:publicationType
Journal Article, Comparative Study